Illinois Bets on Biomarkers to Battle Preterm Births

SPRINGFIELD, IL – June 23, 2026 – In a move that signals a significant shift in public health policy, Illinois is poised to become a national leader in maternal care. A recently passed law amends the state's Public Aid Code, mandating Medicaid coverage for an innovative class of proteomic blood tests designed to predict the risk of preterm birth, a persistent and costly challenge for families and healthcare systems alike. This legislative action places a powerful new tool in the hands of clinicians and could reshape the prenatal journey for the nearly 50,000 individuals who give birth on Medicaid in the state each year.

The new policy not only covers the diagnostic tests themselves but also the subsequent care management and interventions proven to improve outcomes. At the center of this development is the PreTRM® Test, developed by Sera Prognostics. As the only broadly validated, commercially available test of its kind, it's set to play a pivotal role in the implementation of this new mandate. While the specifics of coverage and timing are still being ironed out, the message from Springfield is clear: Illinois is investing in predictive technology to build a more proactive and equitable system of maternal healthcare.

A New Standard for Maternal Health

For years, public health officials have grappled with the devastating impact of preterm birth, defined as birth before 37 weeks of gestation. It remains the leading cause of infant mortality and long-term disability, with the March of Dimes consistently giving the United States a near-failing grade for its high rates. In Illinois alone, more than 13,000 babies were born prematurely in 2024, a rate of about 250 per week. This legislation, identified as Senate Bill 3637, is a direct response to that crisis.

By requiring Medicaid to cover proteomic testing, Illinois is effectively removing the financial barrier to early risk identification for a population that is often most vulnerable. Medicaid finances nearly half of all births in the U.S. and a significant portion in Illinois, making this policy a powerful lever for change.

"We are encouraged to see policymakers prioritizing innovative, evidence-based approaches to improving maternal health," said Zhenya Lindgardt, President and CEO of Sera Prognostics, in a statement. "Expanding access to proteomic testing represents an important step toward enabling earlier identification of risk and more personalized care for pregnant individuals."

The policy is a departure from the traditional, reactive model of care. Instead of waiting for symptoms to appear, clinicians will be able to screen asymptomatic, single-pregnancy patients with a simple blood draw between 18 and 20 weeks of gestation. This early warning allows for a paradigm shift toward prevention, enabling personalized interventions that can significantly alter the course of a pregnancy.

The Science of Prediction

The technology at the heart of this policy shift is proteomics—the large-scale study of proteins. The PreTRM® Test analyzes a specific set of protein biomarkers in a pregnant person’s blood that are highly predictive of the body preparing for labor too early. This isn't a crystal ball, but a sophisticated risk assessment tool grounded in years of clinical research.

The test's efficacy is supported by a landmark randomized controlled trial known as the PRIME study, published earlier this year. The study of over 5,000 women found that when the PreTRM test was paired with targeted interventions—such as progesterone, low-dose aspirin, and dedicated nurse-led care—the results were dramatic. High-risk pregnancies saw 56% fewer births before 32 weeks and a 20% reduction in neonatal intensive care unit (NICU) admissions. For every four patients screened, the strategy saved one day in the NICU, a metric that represents immense emotional and financial relief for families.

However, the medical community's adoption of new technology is often a measured process. The American College of Obstetricians and Gynecologists (ACOG), a leading professional body, still currently describes maternal serum biomarker screening for preterm birth as "investigational." This cautious stance highlights the ongoing dialogue within medicine about when and how to integrate cutting-edge diagnostics into standard practice.

"The data is compelling, but changing practice standards is a marathon, not a sprint," commented one maternal-fetal medicine specialist not affiliated with the company. "What Illinois is doing is accelerating that process through policy. It forces the system to engage with the evidence and adapt, which can be a good thing, provided the implementation is thoughtful and provider-led."

The Economics of Prevention

Beyond the undeniable human benefit of healthier babies and mothers, a powerful economic argument underpins Illinois's decision. The financial toll of preterm birth is staggering. Nationally, the annual cost was estimated at $25 billion in 2016. For Illinois, the societal cost—factoring in medical care, special education, and lost productivity—is estimated to be around $67,000 for each preterm infant.

Investing in prevention, therefore, is not just a healthcare decision but a sound fiscal one. A cost-effectiveness study conducted by Carelon Research projected that using a risk-screening-and-treat strategy with the PreTRM test could lead to substantial savings. The model predicted an $863 net savings per pregnant woman in a commercially insured population, driven by a 20% reduction in preterm births and a 10% drop in NICU admissions. If those figures hold true for the Illinois Medicaid population, the state's investment could yield significant returns, freeing up resources within a strained healthcare budget.

This proactive approach aligns with a broader understanding that the most expensive healthcare is often the emergency care required when preventative measures fail. By funding a test that costs hundreds of dollars, the state hopes to avoid tens of thousands of dollars in NICU stays and a lifetime of associated costs for children with long-term complications from prematurity.

A Ripple Effect Across the Nation?

Illinois may be the first state to mandate this specific coverage through legislation, but it is unlikely to be the last. The move establishes a critical precedent, creating a policy blueprint for other states looking to tackle their own high rates of preterm birth. Sera Prognostics has already launched a Medicaid pilot program in Nevada and is reportedly in talks with several other states.

The initiative also aligns with a national push for more comprehensive maternal healthcare. Federal agencies and medical associations have been advocating for policies that expand access to care and promote research into preterm birth prevention. The establishment of a Medicare reimbursement rate for the PreTRM test in 2022, while not directly applicable to most pregnancies, was an important step in legitimizing the technology within the complex U.S. payer system.

As Illinois moves from legislation to implementation, all eyes will be on the real-world results. Success will depend on effective collaboration between state officials, healthcare providers, and technology partners. If the state can demonstrate improved outcomes and cost savings, its bold bet on biomarkers could very well become the new gold standard in the national fight for healthier mothers and babies.